Evidence map›Paper›PMID 35035660›Full record

ArticleOxidative medicine and cellular longevity2022

BACH1: A Potential Predictor of Survival in Early-Stage Lung Adenocarcinoma.

Jin Zhou, Zheming Liu, Huibo Zhang, Tianyu Lei, Jiahui Liu, Yaqi Zhao, Yi Yao, Qibin Song

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxidative medicine and cellular longevity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jin ZhouCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Zheming LiuCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Huibo ZhangCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Tianyu LeiCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Jiahui LiuAnesthesiology Department, Renmin Hospital of Wuhan University, Wuhan, China.
Yaqi ZhaoCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Yi YaoCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0003-3110-1720
Qibin SongCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.ORCID https://orcid.org/0000-0002-4350-0916
Wuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRecent researches showed the vital role of BACH1 in promoting the metastasis of lung cancer. We aimed to explore the value of BACH1 in predicting the overall survival (OS) of early-stage (stages I-II) lung adenocarcinoma.

resultsBACH1 was an independent prognostic factor for lung adenocarcinoma. High-expression BACH1 cases had worse OS. BACH1-based prognostic model showed an ideal C-index and

conclusionOur research confirmed that BACH1 was an important predictor of prognosis in early-stage lung adenocarcinoma. The higher the expression of BACH1, the worse OS of the patients.

Indexed as

Adenocarcinoma of LungAgedFemaleHumansLung NeoplasmsMaleNeoplasm StagingPrognosisSurvival Analysis

Identifiers

PMID35035660
PMCPMC8758312
OpenAlexW4206783017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.